SRR5903553
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.460
- KRAS_SIGNALING_DN+0.320
- INTERFERON_GAMMA_RESPONSE+0.300
- MYC_TARGETS_V2+0.170
- SPERMATOGENESIS+0.120
- ALLOGRAFT_REJECTION+0.110
- IL6_JAK_STAT3_SIGNALING+0.070
- CHOLESTEROL_HOMEOSTASIS+0.030
- PANCREAS_BETA_CELLS+0.010
- INFLAMMATORY_RESPONSE+0.000
Top 10 suppressed
- TGF_BETA_SIGNALING-0.610
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- PROTEIN_SECRETION-0.500
- UV_RESPONSE_DN-0.470
- MITOTIC_SPINDLE-0.420
- MYC_TARGETS_V1-0.420
- ANGIOGENESIS-0.410
- ANDROGEN_RESPONSE-0.390
- HEDGEHOG_SIGNALING-0.390
- NOTCH_SIGNALING-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R73 | — | — | 0.859 |
| 2 | SRR8392892 | — | cohortA1 | 0.859 |
| 3 | TCGA-49-AARQ-01A-11R-A41B-07 | — | cohortA1 | 0.854 |
| 4 | SJEPD027_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.846 |
| 5 | TCGA-49-AAQV-01A-11R-A39D-07 | — | cohortA1 | 0.843 |
| 6 | SRR33346946 | — | — | 0.841 |
| 7 | SRR25617833 | — | B | 0.835 |
| 8 | TCGA-49-AAR2-01A-11R-A39D-07 | — | cohortA3 | 0.835 |
| 9 | MDT-AP-1327 | Med | Medulloblastoma | 0.834 |
| 10 | TCGA-MN-A4N5-01A-11R-A24X-07 | — | cohortA1 | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |